Compare PTC & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTC | ILMN |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 19.4B |
| IPO Year | 1995 | 2000 |
| Metric | PTC | ILMN |
|---|---|---|
| Price | $137.06 | $131.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 17 |
| Target Price | ★ $182.83 | $124.24 |
| AVG Volume (30 Days) | 1.0M | ★ 1.2M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 94.87 | ★ 170.87 |
| EPS | 1.39 | ★ 5.45 |
| Revenue | $2,739,226,000.00 | ★ $4,343,000,000.00 |
| Revenue This Year | $0.43 | $6.52 |
| Revenue Next Year | $6.22 | $5.60 |
| P/E Ratio | $98.28 | ★ $24.26 |
| Revenue Growth | ★ 19.18 | N/A |
| 52 Week Low | $130.89 | $69.88 |
| 52 Week High | $219.69 | $155.53 |
| Indicator | PTC | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 36.80 | 58.34 |
| Support Level | N/A | $127.99 |
| Resistance Level | $148.00 | $136.86 |
| Average True Range (ATR) | 4.48 | 4.99 |
| MACD | -0.20 | 0.94 |
| Stochastic Oscillator | 36.70 | 89.24 |
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.